Quasi-experimental studies

We are searching the literature every day and collecting data for each quasi-experimental study of COVID-19 treatment identified.

In this table, we report the main characteristics of the quasi-experimental studies identified.

The link in the column "Overall risk of bias" will give you access to a complete description of the assessment of each risk of bias domain with supports for judgement.

Treatment comparisons

We report below the forest plots for the main treatment comparisons.

Please choose a Treatment Comparison:

  • Hydroxychloroquine vs Standard care
  • Chloroquine vs Standard care
  • Chloroquine + Azithromycin /Clarithromycin vs Standard care
  • Hydroxychloroquine + Azithromycin/Clarithromycin vs Standard care
  • Convalescent plasma vs Standard care
  • Famotidine vs No Famotidine

Reboot the table and see all comparisons

Trial Comparisons Design Participants Sample size Overall risk of bias Full description
Treatment 1 Treatment 2
N/A
Geleris J, N Engl J Med, 2020
Full text
Commentary
Hydroxychloroquine Standard care Quasi-Experimental Study Patients with confirmed COVID-19 (unclear severity) admitted to one center in the USA. N=1085
Serious
Details
Full description
N/A
Mahevas M, Bmj, 2020
Full text
Full text
Commentary
Commentary
Hydroxychloroquine Standard care Quasi-Experimental Study Patients with COVID-19 (moderate), hospitalized and requiring oxygen, admitted to four centers in France N=181
Moderate
Details
Full description
*
Mehra, MR, Lancet, 2020
Full text
Pubpeer
Chloroquine Standard care Quasi-Experimental Study Patients with confirmed COVID-19 (of unclear severity) admitted to 671 hospitals across 6 continents N=96122
Serious
Details
Full description
Chloroquine + Azithromycin/Clarithromycin Standard care
Hydroxychloroquine Standard care
Hydroxychloroquine + Azithromycin/Clarithromycin Standard care
N/A
Liu, STH, medRxiv, 2020
Full text
Commentary
Convalescent plasma Standard care Quasi-Experimental Study Patients with COVID-19 (severe/critical) admitted to a single centre in the USA. N=195
Moderate
Details
Full description
N/A
Freedberg, DE, medRxiv, 2020
Full text
Famotidine No famotidine Quasi-Experimental Study Patients with confirmed COVID-19 (moderate/severe) admitted to a single centre in the USA. N=504
Serious
Details
Full description

We acknowledge that we may have been unable to extract some information from pre-prints, as they represent preliminary forms of scientific communication. We perform daily database searches to identify if an included pre-print has been published in a scientific journal, and we will use the published paper to update our extraction

We recognize that our process might not be perfect. Please contact us if you identify an error